Compare · ECOR vs MDT
ECOR vs MDT
Side-by-side comparison of electroCore Inc. (ECOR) and Medtronic plc. (MDT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ECOR and MDT operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- MDT is the larger of the two at $122.09B, about 1621.8x ECOR ($75.3M).
- Over the past year, ECOR is up 62.7% and MDT is down 1.1% - ECOR leads by 63.8 points.
- MDT has been more active in the news (35 items in the past 4 weeks vs 1 for ECOR).
- MDT has more recent analyst coverage (25 ratings vs 2 for ECOR).
- Company
- electroCore Inc.
- Medtronic plc.
- Price
- -
- -
- Market cap
- $75.3M
- $122.09B
- 1M return
- -29.51%
- +2.12%
- 1Y return
- +62.73%
- -1.05%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 1
- 35
- Recent ratings
- 2
- 25
electroCore Inc.
electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld delivery system for multi-year use prescribed on a monthly basis. The company was founded in 2005 and is headquartered in Rockaway, New Jersey.
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Latest ECOR
- Director Errico Thomas J. bought $49,082 worth of shares (5,000 units at $9.82), increasing direct ownership by 1% to 363,904 units (SEC Form 4)
- Amendment: Officer Fox Michael bought $49,004 worth of shares (5,000 units at $9.80), increasing direct ownership by 4% to 130,000 units (SEC Form 4)
- Officer Fox Michael was granted 5,000 shares, increasing direct ownership by 4% to 130,000 units (SEC Form 4)
- Director Theofilos James Charles was granted 11,123 shares, increasing direct ownership by 47% to 34,670 units (SEC Form 4)
- Director Goldstein Julie Ann was granted 11,123 shares, increasing direct ownership by 11% to 112,510 units (SEC Form 4)
- Director Wilber Patricia was granted 11,123 shares, increasing direct ownership by 15% to 83,448 units (SEC Form 4)
- Director Errico Thomas J. was granted 15,572 shares, increasing direct ownership by 5% to 358,904 units (SEC Form 4)
- Director Bonfiglioli Elena was granted 11,123 shares, increasing direct ownership by 36% to 41,672 units (SEC Form 4)
- Officer Fox Michael was granted 55,000 shares, increasing direct ownership by 79% to 125,000 units (SEC Form 4)
- Officer Lev Joshua S. was granted 55,000 shares, increasing direct ownership by 65% to 139,889 units (SEC Form 4)
Latest MDT
- SEC Form 4 filed by Medtronic plc.
- SEC Form 4 filed by Medtronic plc.
- Medtronic Named to TIME Best Inventions of 2026 List for Stealth AXiS™ surgical system and Corsano™* multi-parameter wearable
- MiniMed Completes Separation from Medtronic
- Medtronic Completes Separation of MiniMed Group, Inc.
- SEC Form 144 filed by Medtronic plc.
- Amendment: SEC Form SC TO-I/A filed by Medtronic plc.
- SEC Form 425 filed by Medtronic plc.
- Medtronic Announces Final Results of MiniMed Group, Inc. Exchange Offer
- Amendment: SEC Form SC TO-I/A filed by Medtronic plc.